Guideline for the Treatment of Leprosy by New Quinolones
-
- Gidoh Masaichi
- Leprosy Research Center, National Institute of Infectious Diseases
-
- Namisato Masako
- National Sanatorium, Kuryu-Rakusenen
-
- Kumano Kimiko
- Hyogo Medical Center for Adults
-
- Goto Masamichi
- Kagoshima University Graduate School of Medical and Dental Sciences
-
- Nogami Reiko
- National Sanatorium, Kikuchi-Keifuen
-
- Ozaki Motoaki
- National Sanatorium, Nagashima-Aiseien
Bibliographic Information
- Other Title
-
- ニューキノロン使用指針
Search this article
Abstract
Ofloxacin(OFLX) is often applied today as a substitution drug of MDT for drug resistance to dapsone, rifampicin or clofazimine. However, OFLX resistance is also becoming a great concern. Low and/or irregular administration are considered to be the major causes of OFLX resistance. OFLX should be used as a combined therapy, and minimal daily dose of 400mg of OFLX or 200 ?? 300mg of levofloxacin is required. Quinolone resistance should be considered when no improvement of clinical and/or bacterial index is observed after the treatment for 6 months. In such cases, resistance gene detection is necessary.
Journal
-
- JAPANESE JOURNAL OF LEPROSY
-
JAPANESE JOURNAL OF LEPROSY 73 (1), 65-67, 2004
Japanese Leprosy Association
- Tweet
Details 詳細情報について
-
- CRID
- 1390282681300137984
-
- NII Article ID
- 10012123039
-
- NII Book ID
- AN10559906
-
- COI
- 1:STN:280:DC%2BD2c7kt1Gnsw%3D%3D
-
- ISSN
- 1884314X
- 13423681
-
- PubMed
- 15035068
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed